Cross-reactivity of glycan-reactive HIV-1 broadly neutralizing antibodies with parasite glycans

Isabella Huettner, Stefanie A. Krumm, Sonia Serna, Katarzyna Brzezicka, Serena Monaco, Samuel Walpole, Angela Van Diepen, Fiona Allan, Thomas Hicks, Simon Kimuda, Aidan M. Emery, The IAVI Protocol C Investigators & The IAVI African HIV Research Network, Susan Allen, William Kilembe, Shabir Lakhi, Mubiana Inambao, Etienne Karita, Anatoli Kamali, Eduard J. Sanders, Omu AnzalaVinodh Edward, Linda-Gail Bekker, Jianming Tang, Jill Gilmour, Eric Hunter, Matt Price, Elise Landais, Cornelis H. Hokke, Jesus Angulo, Niels Reichardt, Katie J. Doores

Research output: Contribution to journalArticlepeer-review

2 Downloads (Pure)

Abstract

The HIV-1 Envelope glycoprotein (Env) is the sole target for broadly neutralizing antibodies (bnAbs). Env is heavily glycosylated with host-derived N-glycans, and many bnAbs bind to, or are dependent upon, Env glycans for neutralization. Although glycan-binding bnAbs are frequently detected in HIV-infected individuals, attempts to elicit them have been unsuccessful because of the poor immunogenicity of Env N-glycans. Here, we report cross-reactivity of glycan-binding bnAbs with self- and non-self N-glycans and glycoprotein antigens from different life-stages of Schistosoma mansoni. Using the IAVI Protocol C HIV infection cohort, we examine the relationship between S. mansoni seropositivity and development of bnAbs targeting glycan-dependent epitopes. We show that the unmutated common ancestor of the N332/V3-specific bnAb lineage PCDN76, isolated from an HIV-infected donor with S. mansoni seropositivity, binds to S. mansoni cercariae while lacking reactivity to gp120. Overall, these results present a strategy for elicitation of glycan-reactive bnAbs which could be exploited in HIV-1 vaccine development.
Original languageEnglish
Article number110611
JournalCell Reports
Volume38
Issue number13
DOIs
Publication statusPublished - 29 Mar 2022

Cite this